25
Jun
New Delhi: Hyderabad-based drugmaker Hetero, which has approval to manufacture and market the generic version of the experimental COVID-19 drug Remdesivir, has sent 20,000 vials to five states including Maharashtra and Delhi - the two worst affected states in the country. Gujarat and Tamil Nadu are the other two states that will receive the first batch of the drug which is being marketed under the brand name COVIFOR in India. Telangana's capital Hyderabad, where the drugmaker is based, will also receive the first consignment. Hetero has set a target to produce one lakh vials of the drug in two-three weeks. The…
